33 results about "HIV positives" patented technology

The present invention relates to the use of a non-lethal preparative regimen for the treatment of a patient with human immunodeficiency virus (HIV) disease. In a clinical trial, an HIV-positive patient was conditioned by non-lethal doses of irradiation and a chemotherapeutic drug prior to receiving donor bone marrow cells from a baboon. While long-term engraftment of donor cells was not observed, the non-lethal preparative conditioning regimen was able to reduce the viral burden and improved the clinical outcome. Such method is useful for treatment of patients with advanced acquired immunodeficiency syndrome (AIDS).

The invention discloses a monoclonal antibody hybridoma cell expressing an HIV P24 and an application, wherein, through separating HIV virus in an HIV positive infector, the P24 protein gene of the separated virus is enlarged; P24 protein can be obtained through external expression of carriers and purification; after using the purified P24 protein to immunize the mice, the spleen B cells of the immunized mice are separated out, and an hybridoma cell efficiently expressing a P24 monoclonal antibody (whiov-P24C-MoAb, CCTCC NO:C200818) can be obtained by adopting a hybridoma technology; and the P24 monoclonal antibody can be in specific binding with P24 protein of HIV virus for detecting the expression of P24 antigen. The P24 monoclonal antibody can be in specific binding with P24 protein ofHIV virus, interferences of other bad reactions can be reduced when being used for specific detection of P24 protein.

Provided herein are methods for inhibiting proliferation of a microbe associated with a sexually transmitted disease (STD) or infection and for preventing transmission of one or more sexually transmitted diseases in a subject at-risk for acquiring the same, including an HIV positive subject at risk for acquiring another sexually transmitted disease. The methods comprise contacting a microbe or cell thereof associated with the STD or administering to the subject nordihydroguaiaretic acid or a derivative or analog thereof. In HIV positive at-risk subjects one or more anti-retroviral drugs are co-administered.

The invention discloses a primer pair, probe and kit used for quantitative detection total DNAs of HIV-1 and capable of covering multiple subtypes of HIV-1. The sequence of the upstream primer HIV-U1of the primer pair is as shown in SEQ ID No. 1; the sequence of the downstream primer HIV-R1 of the primer pair is as shown in SEQ ID No. 2; the sequence of the probe Probe-HIV is as shown in SEQ ID No. 3. According to the invention, degenerate primers are utilized for high-sensitivity high-specificity detection of HIV DNA, and 12 common subtypes of HIV and rare HIV subtypes can be successfully detected, so the detection kit of the invention has wider subtype detection coverage compared with other conventional commercial detection kits. The primer pair, probe and kit provided by the inventioncan be used for quantification of total HIV DNAs of current prevalent HIV strains in China. A method provided by the invention is simple to operate, can complete procedures from sample DNA extractionto real-time fluorescent quantitative PCR amplification in one day, has low price, can be used for monitoring the persistent infection status of HIV-infected individuals in large cohorts, evaluating the effect of cART treatment, and is also applicable to auxiliary diagnosis of early HIV infection and diagnosis of neonatal infection in HIV-positive mothers.

The present invention relates to two novel crystal forms of a known compound, 1-[5-Methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl] piperazine monomethanesulfonate salt, which are useful for treating humans who are HIV positive, which are identified by a powder X-ray diffraction spectrum known commonly as the "S" and "T" forms.

The invention relates to a method of detecting a HIV-infected cell in a mammal. The method includes detecting an HIV 2-LTR circle DNA molecule obtained from a cell of an HIV-positive mammal, especially an HIV-1-positive human.

A method of treating noninfectious diarrhea in an HIV positive subject includes administering a dose of ibuprofen to the HIV positive subject at regular intervals until stool consistency is improved, diarrhea is alleviated, or the number of bowel movements per day are decreased. The dose is 400 mg of ibuprofen administered every 6 hours. The method may additionally include diagnosing the subject with noninfectious diarrhea, determining the subject does not have certain comorbidities, and/or determining that the subject is not taking any non-steroidal anti-inflammatory drugs. The method may additionally include after administering the ibuprofen, administering a clear liquids diet to the subject, administering an electrolyte supplement to the subject, and/or monitoring the subject for any bleeding from the gastrointestinal tract until stool consistency is improved, until diarrhea is alleviated, or until the number of bowel movements per day are decreased.

The present invention provides methods and formulations for optimizing the anti-cancer and anti-HIV activities of a camptothecin drug, including camptothecin and its related analogs including 9-aminocamptothecin and 9-nitrocamptothecin. The invention involves methodologies and formulations that limit human serum albumin-mediated reduction of the anti-cancer and anti-HIV effects of the camptothecins, and the methods and formulations provide combination therapies in which binding of the camptothecin agent to human serum albumin can be modulated by the administration of a competing agent that also binds human serum albumin. Reduced camptothecin drug binding to human serum albumin can result in elevated camptothecin free drug levels and thus improve the effectiveness of treatment regimens involving these drugs. Further agents such as methotrexate and AZT can also be used in cancer and HIV-positive patients employing camptothecin drugs.

The invention provides an information collection method and information collection device. The information collection method comprises the following steps: collecting detection result information of target test paper through a sensor, wherein the target test paper is used human immunodeficiency virus self-detection HIVST test paper; and sending the detection result information to an information acquisition center. The information acquisition center can acquire the detection result information of the target test paper, and solved are the problems that as most self-checking motives have high-risk behaviors, and potential infected people cannot be primarily screened and rechecked in time due to condition limitation, the estimation of the HIV positive epidemic condition possibly has large deviation, a target population of HIVST, i.e., a sexual minority population, especially a high-risk population with HIV infection risk between male and male sexual behavior persons, is low in consciousness when the population returns a self-inspection result to health service personnel, and cannot effectively obtain real data after the self-inspection population is subjected to HIVST.

The invention discloses a rapid detection method, liquid chip and kit for four human infectious diseases, and relates to the technical field of life sciences and biology. The liquid chip mainly includes 60-100 parts of a sample diluent, 10-20 parts of oligonucleotides for HIV detection, 5-10 parts of HIV positive control, 0.1-0.2 part of insulin, 20-50 parts of amino acids, 0.2-0.5 part of DNA polymerase, 0.2-0.5 part of reverse transcriptase, 0.2-0.5 part of RNA polymerase, 10-20 parts of a nucleic acid releasing agent and 5-10 parts of nucleotide-targeted detection primers. According to therapid detection method, liquid chip and kit for the four human infectious diseases, high activity of cells and viruses can be maintained through coordination of the insulin and amino acids when AIDS,syphilis, hepatitis C and hepatitis B are detected, and the process of reactions of AIDS, syphilis, hepatitis C and hepatitis B viruses can be catalyzed and accelerated through combination of the DNApolymerase, reverse transcriptase and RNA polymerase, so that the detection effect of the detection kit is increased greatly, and the detection effect is more accurate.

The invention relates to panels of biomarkers for diagnosing and/or monitoring the progression of an active mycobacterial infection or for diagnosing the absence of a mycobacterial infection, particularly tuberculosis. Such diagnosis and/or monitoring may be differential diagnosis between active tuberculosis patients and patients with latent, non-progressing tuberculosis or healthy or sick patients, irrespective of whether the patients have been characterised as being sputum smear positive or sputum smear negative, and/or irrespective of whether they have been characterised as being HIV positive or HIV negative. The above pertain in all aspects both to pulmonary and extra pulmonary Mycobacterium tuberculosis infections, with Mycobacterium tuberculosis being the causative organism in tuberculosis.